Palivizumab is approved for prevention of RSV disease, and ribavirin is approved for treatment of RSV infections but its efficacy in high-risk patients has not been conclusively established.

a preliminary study was not conducted to gain an understanding of why physicians routinely prescribed ribavirin and antimicrobials for infants and young children hospitalized with RSV-related ...

The company has also developed injectable and inhalation formulations ... approved to treat severe RSV infection in high-risk children and infants. Lastly, ribavirin is an antiviral nucleoside ...